Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Nature. 2017 Dec 21;552(7685):368-373. doi: 10.1038/nature25023. Epub 2017 Dec 13.
The mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and metabolism in response to nutrients, energy levels, and growth factors. It contains the atypical kinase mTOR and the RAPTOR subunit that binds to the Tor signalling sequence (TOS) motif of substrates and regulators. mTORC1 is activated by the small GTPase RHEB (Ras homologue enriched in brain) and inhibited by PRAS40. Here we present the 3.0 ångström cryo-electron microscopy structure of mTORC1 and the 3.4 ångström structure of activated RHEB-mTORC1. RHEB binds to mTOR distally from the kinase active site, yet causes a global conformational change that allosterically realigns active-site residues, accelerating catalysis. Cancer-associated hyperactivating mutations map to structural elements that maintain the inactive state, and we provide biochemical evidence that they mimic RHEB relieving auto-inhibition. We also present crystal structures of RAPTOR-TOS motif complexes that define the determinants of TOS recognition, of an mTOR FKBP12-rapamycin-binding (FRB) domain-substrate complex that establishes a second substrate-recruitment mechanism, and of a truncated mTOR-PRAS40 complex that reveals PRAS40 inhibits both substrate-recruitment sites. These findings help explain how mTORC1 selects its substrates, how its kinase activity is controlled, and how it is activated by cancer-associated mutations.
雷帕霉素复合物 1 (mTORC1)的机械靶点控制细胞生长和代谢,以响应营养物质、能量水平和生长因子。它包含非典型激酶 mTOR 和 RAPTOR 亚基,该亚基与底物和调节剂的 Tor 信号序列(TOS)基序结合。mTORC1 被小 GTPase RHEB(富含大脑的 Ras 同源物)激活,并被 PRAS40 抑制。在这里,我们展示了 mTORC1 的 3.0 ångström 低温电子显微镜结构和激活的 RHEB-mTORC1 的 3.4 ångström 结构。RHEB 从激酶活性位点远端结合 mTOR,但引起全局构象变化,使活性位点残基变构重新排列,从而加速催化。与癌症相关的高活性突变映射到维持非活性状态的结构元件,我们提供了生化证据表明它们模拟 RHEB 解除自动抑制。我们还展示了 RAPTOR-TOS 基序复合物的晶体结构,该结构定义了 TOS 识别的决定因素,mTOR FKBP12-雷帕霉素结合(FRB)域-底物复合物的结构,该复合物建立了第二个底物募集机制,以及截断的 mTOR-PRAS40 复合物的结构,该复合物揭示了 PRAS40 抑制两个底物募集位点。这些发现有助于解释 mTORC1 如何选择其底物,其激酶活性如何受到控制,以及如何被与癌症相关的突变激活。